Northern Trust Corp reduced its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 51.6% during the second quarter, HoldingsChannel.com reports. The firm owned 1,043,770 shares of the biopharmaceutical company’s stock after selling 1,113,190 shares during the period. Northern Trust Corp’s holdings in Celldex Therapeutics were worth $526,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in Celldex Therapeutics by 2,633.4% in the 2nd quarter. Renaissance Technologies LLC now owns 4,220,687 shares of the biopharmaceutical company’s stock worth $2,126,000 after purchasing an additional 4,066,273 shares during the period. Acadian Asset Management LLC grew its position in shares of Celldex Therapeutics by 378.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 915,863 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Celldex Therapeutics by 27.7% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 900,185 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 195,147 shares during the last quarter. Paloma Partners Management Co grew its position in shares of Celldex Therapeutics by 5,357.8% in the 2nd quarter. Paloma Partners Management Co now owns 640,799 shares of the biopharmaceutical company’s stock worth $323,000 after buying an additional 629,058 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Celldex Therapeutics in the 2nd quarter worth approximately $322,000. 27.78% of the stock is currently owned by institutional investors and hedge funds.
CLDX has been the topic of a number of recent analyst reports. Jefferies Financial Group reiterated a “hold” rating on shares of Celldex Therapeutics in a research report on Friday, August 10th. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Celldex Therapeutics in a research report on Monday, November 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $2.19.
Shares of CLDX stock opened at $0.26 on Friday. Celldex Therapeutics, Inc. has a fifty-two week low of $0.25 and a fifty-two week high of $3.09.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.07. The firm had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.08 million. Celldex Therapeutics had a negative return on equity of 51.88% and a negative net margin of 1,296.96%. On average, equities research analysts anticipate that Celldex Therapeutics, Inc. will post -0.39 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/12/08/northern-trust-corp-has-526000-holdings-in-celldex-therapeutics-inc-cldx.html.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Featured Story: Do Tariffs Work?
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.